PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2337
https://www.valueinhealthjournal.com/article/S1098-3015(19)34715-1/fulltext
Title :
PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34715-1&doi=10.1016/j.jval.2019.09.2337
First page :
Section Title :
Open access? :
No
Section Order :
12039